Single User License
INR 100305
Site License
INR 200610
Corporate User License
INR 300915

Service Tax Additional

select a format

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

Celgene Corporation-Product Pipeline Review-2015

Celgene Corporation-Product Pipeline Review-2015

  Request for Sample Report

Executive Summary

Celgene Corporation-Product Pipeline Review-2015


Global Markets Direct's, 'Celgene Corporation-Product Pipeline Review-2015', provides an overview of the Celgene Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Celgene Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Celgene Corporation including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Celgene Corporation's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Celgene Corporation's pipeline products

Reasons To Buy

Evaluate Celgene Corporation's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Celgene Corporation in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Celgene Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Celgene Corporation and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Celgene Corporation

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Celgene Corporation and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 8

Celgene Corporation Snapshot 9

Celgene Corporation Overview 9

Key Information 9

Key Facts 9

Celgene Corporation-Research and Development Overview 10

Key Therapeutic Areas 10

Celgene Corporation-Pipeline Review 17

Pipeline Products by Stage of Development 17

Pipeline Products-Monotherapy 18

Pipeline Products-Partnered Products 19

Partnered Products/Combination Treatment Modalities 20

Pipeline Products-Out-Licensed Products 22

Out-Licensed Products/Combination Treatment Modalities 23

Celgene Corporation-Pipeline Products Glance 24

Celgene Corporation-Late Stage Pipeline Products 24

Pre-Registration Products/Combination Treatment Modalities 24

Phase III Products/Combination Treatment Modalities 25

Celgene Corporation-Clinical Stage Pipeline Products 26

Phase II Products/Combination Treatment Modalities 26

Phase I Products/Combination Treatment Modalities 27

Celgene Corporation-Early Stage Pipeline Products 28

Preclinical Products/Combination Treatment Modalities 28

Discovery Products/Combination Treatment Modalities 29

Celgene Corporation-Drug Profiles 30

apremilast 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

lenalidomide 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

paclitaxel albumin bound 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

amrubicin hydrochloride 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

azacitidine 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

pomalidomide 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

romidepsin 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

CC-11050 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

CC-220 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

cenplacel-L 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

GI-6301 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

mongersen 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

PDA-002 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

spebrutinib besylate 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

AG-221 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

CC-223 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

ARRY-382 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

CC-115 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

CC-122 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

CC-90001 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

CC-90002 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

CC-90003 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

CTP-730 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

EPZ-5676 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Stem Cell Therapy for Hematological Malignancies and Non-Malignant Disorders 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

ABI-013 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Antibody for Oncology 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

AVL-181 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

AVL-192 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

CC-0730671 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

CC-2142 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

CC-509 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

CC-539 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

CNX-1351 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

IMiDxl 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

Small Molecules for Cancer and Inflammation 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Small Molecules for Undisclosed Indication 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Antibody for Undisclosed Indication 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

CC-0739623 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

CC-2141 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

CSC-1 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

Drug to Inhibit Kinase for Inflammation 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

Drugs for Hematology and Oncology 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

EPIpros-1 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

EPIpros-2 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

Monoclonal Antibody Conjugate to Inhibit Protein S100-A9 for MDS 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Small Molecule to Inhibit Brutons Tyrosine Kinase for Inflammation 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

Small Molecules for Inflammation 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

Small Molecules for Inflammation and Cancer 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

Small Molecules for Malaria 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

Celgene Corporation-Pipeline Analysis 101

Celgene Corporation-Pipeline Products by Target 101

Celgene Corporation-Pipeline Products by Route of Administration 103

Celgene Corporation-Pipeline Products by Molecule Type 104

Celgene Corporation-Pipeline Products by Mechanism of Action 105

Celgene Corporation-Recent Pipeline Updates 107

Celgene Corporation-Dormant Projects 140

Celgene Corporation-Discontinued Pipeline Products 142

Discontinued Pipeline Product Profiles 142

CC-1088 142

satraplatin 142

Celgene Corporation-Company Statement 143

Celgene Corporation-Locations And Subsidiaries 145

Head Office 145

Other Locations & Subsidiaries 145

Appendix 151

Methodology 151

Coverage 151

Secondary Research 151

Primary Research 151

Expert Panel Validation 151

Contact Us 151

Disclaimer 152

List of Tables

Celgene Corporation, Key Information 9

Celgene Corporation, Key Facts 9

Celgene Corporation-Pipeline by Indication, 2015 11

Celgene Corporation-Pipeline by Stage of Development, 2015 17

Celgene Corporation-Monotherapy Products in Pipeline, 2015 18

Celgene Corporation-Partnered Products in Pipeline, 2015 19

Celgene Corporation-Partnered Products/ Combination Treatment Modalities, 2015 20

Celgene Corporation-Out-Licensed Products in Pipeline, 2015 22

Celgene Corporation-Out-Licensed Products/ Combination Treatment Modalities, 2015 23

Celgene Corporation-Pre-Registration, 2015 24

Celgene Corporation-Phase III, 2015 25

Celgene Corporation-Phase II, 2015 26

Celgene Corporation-Phase I, 2015 27

Celgene Corporation-Preclinical, 2015 28

Celgene Corporation-Discovery, 2015 29

Celgene Corporation-Pipeline by Target, 2015 101

Celgene Corporation-Pipeline by Route of Administration, 2015 103

Celgene Corporation-Pipeline by Molecule Type, 2015 104

Celgene Corporation-Pipeline Products by Mechanism of Action, 2015 106

Celgene Corporation-Recent Pipeline Updates, 2015 107

Celgene Corporation-Dormant Developmental Projects,2015 140

Celgene Corporation-Discontinued Pipeline Products, 2015 142

Celgene Corporation, Other Locations 145

Celgene Corporation, Subsidiaries 145

List of Figures

Celgene Corporation-Pipeline by Top 10 Indication, 2015 11

Celgene Corporation-Pipeline by Stage of Development, 2015 17

Celgene Corporation-Monotherapy Products in Pipeline, 2015 18

Celgene Corporation-Partnered Products in Pipeline, 2015 19

Celgene Corporation-Out-Licensed Products in Pipeline, 2015 22

Celgene Corporation-Pipeline by Top 10 Target, 2015 101

Celgene Corporation-Pipeline by Top 10 Route of Administration, 2015 103

Celgene Corporation-Pipeline by Top 10 Molecule Type, 2015 104

Celgene Corporation-Pipeline Products by Top 10 Mechanism of Action, 2015 105

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Current R&D Portfolio of Celgene Corporation; Celgene Corporation - Key Therapeutics; Celgene Corporation - Pipeline Overview and Promising Molecules; Celgene Corporation - News; Celgene Corporation - Latest Updates; Celgene Corporation - Pipeline; Celgene Corporation - Discontinued/Dormant Projects

Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]